Celularity Inc (CELU) · Oct 29, 2026 · Material agreement
Peptide manufacturing agreement — No economics, committed volumes, or revenue terms disclosed
Celularity’s new manufacturing agreement expands beyond cell therapy into peptide APIs, but commercial timing, volumes and revenue remain undisclosed.
Celularity is a cash-constrained regenerative-medicine company trying to turn its New Jersey facility and manufacturing capabilities into near-term third-party revenue; its latest filing reported just $0.6 million of cash at June 30, 2026, alongside a $53.3 million working-capital deficit and substantial doubt about continued operations. This agreement directly supports that transition. Celularity has entered an exclusive deal to provide purification, processing, testing and manufacturing for Vesalius’s Peptual peptide APIs, adding a new contract-manufacturing vertical alongside its cell-therapy and biomaterials businesses.
The strategic fit is real, but the financial impact is not yet measurable. The filing gives no upfront payment, minimum volumes, pricing, launch date or committed revenue, so this is an infrastructure-utilization opportunity rather than a booked commercial win. Celularity will initially work with supplier-provided bulk peptide material and still has to establish and qualify peptide-specific processes and quality systems. 〔0〕
Regulatory optionality is doing much of the work in the announcement. Potential supply to U.S. compounding pharmacies depends on FDA and Pharmacy Compounding Advisory Committee actions, and the products are not FDA-approved. The deal also explicitly excludes GLP-1 receptor agonists and other weight-loss peptides, limiting exposure to the most obvious peptide-demand narrative. 〔1〕
The filing is an incremental business-model positive, not a near-term liquidity solution. Celularity’s recent operating plan called for manufacturing revenue and other commercial improvements to help reach positive monthly operating cash flow by the end of the first quarter of 2027, but this collaboration does not itself guarantee that outcome. The company is explicit that commercial supply could be delayed or never occur. 〔2〕
Bottom line: The deal gives Celularity a credible new use for its manufacturing infrastructure and modestly improves the commercial story. It does not yet change the cash picture because the economics, timing and regulatory path remain open.
Peptide process qualification and regulatory eligibility decisions
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!